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Abstract
Introduction Experimental streptococcal cell wall (SCW)-
induced arthritis is characterized by two successive phases of
the disease. The acute phase occurs early and is associated
with an inflammatory process and neutrophil infiltration into the
synovium. The second chronic phase is related to effector T-cell
activation and the dysregulation of macrophage function.
Creation of an immunomodulatory environment has been
attributed to apoptotic cells themselves, apoptotic cell uptake
by phagocytes as well as a less sensibility of phagocytes
capturing apoptotic bodies to activation. Therefore we
evaluated the potential of apoptotic cell injection to influence the
course of inflammation in SCW-induced arthritis in rats.
Methods Rat apoptotic thymocytes were injected
intraperitoneally (2 × 108) in addition to an arthritogenic dose of
systemic SCW in LEW female rats. Control rats received SCW
immunization and PBS. Rats were then followed for arthritis
occurrence and circulating cytokine detection. At sacrifice,
regulatory T cells (Tregs) and macrophages were analyzed.
Results Apoptotic cell injection profoundly suppressed joint
swelling and destruction typically observed during the acute and
chronic phases of SCW-induced arthritis. Synovial inflammatory
cell infiltration and bone destruction were also markedly
suppressed. Ex vivo experiments revealed reduced levels of
TNF in cultures of macrophages from rats challenged with SCW
in the presence of apoptotic thymocytes as well as reduced
macrophage response to lipopolysaccharide. Moreover,
apoptotic cell injection induced higher Foxp3+ Tregs in the
lymphoid organs, especially in the draining lymph nodes.
Conclusions Our data indicate that apoptotic cells modulate
macrophage function and result in Treg generation/increase.
This may be involved in inhibition of inflammation and
amelioration of arthritis. This highlights and confirms previous
studies showing that in vivo generation of Tregs using apoptotic
cell injection may be a useful tool to prevent and treat
inflammatory autoimmune responses.
Introduction
The most salient feature of apoptosis is the lack of inflamma-
tory responses or tissue damage. Several mechanisms of
peripheral tolerance have been described to explain this lack
of immune responses against apoptotic cell-derived antigens
[1,2]. First, apoptotic cells themselves possess immunomodu-
latory properties by the release of transforming growth factor
beta (TGFβ) stored in their cytoplasm [3]. Then professional
phagocytes, such as macrophages and some dendritic cell
subsets [1,4], can also favor an immunomodulatory environ-
ment by the release of anti-inflammatory cytokines during
apoptotic cell uptake. Such immunomodulatory milieu consists
mainly of TGFβ and IL-10 [5-7].
BSA: bovine serum albumin; DMEM: Dulbecco's modified Eagle's medium; ELISA: enzyme-linked immunosorbent assay; FBS: fetal bovine serum; 
Foxp3: forkhead box P3; H & E: hematoxylin and eosin; IL: interleukin; LPS: lipopolysaccharide; mAB: monoclonal antibody; PBS: phosphate-buffered 
saline; RA: rheumatoid arthritis; SCW: streptococcal cell wall; Treg: regulatory T cell; TGFβ: transforming growth factor beta; TNF: tumor necrosis 
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Recently, the role of TGFβ in immune tolerance has been high-
lighted by its direct and indirect effects on autoimmunity and
inflammation [6,8]. Moreover, TGFβ is a key factor to convert
peripheral naive CD4+CD25- T cells into CD4+CD25+Foxp3+
regulatory T cells (Tregs), in vitro [9] as well as in vivo [8].
Also, the TGFβ signaling pathway has also been shown to be
critical for natural Treg development [10].
The feasibility of cellular therapy based on the immunomodula-
tory properties of apoptotic cells has already been evaluated
in different experimental models to restore or induce immune
tolerance. Indeed, apoptotic cell injection favors allogeneic
hematopoietic cell engraftment, favors allograft heart survival
and decreases acute graft-versus-host disease (for a review
see [11]). Moreover, spontaneous type I diabetes occurrence
in NOD mice could be delayed by injection of apoptotic beta
cells [12]. These beneficial effects have been mainly related to
TGFβ and/or Tregs [11-13].
Although such an approach of apoptotic cell infusion has not
yet been used directly in patients, the immunomodulatory
properties of apoptotic cells may play a role in the tolerogenic
effects of blood product transfusions [14] or of extracorporeal
photochemotherapy [15,16]. Indeed, the beneficial effects of
extracorporeal photochemotherapy in the treatment of severe
chronic or acute graft-versus-host disease have been associ-
ated with the significant number of the apoptotic cells gener-
ated during extracorporeal photochemotherapy [15,16]. While
apoptotic cell instillation prevents and treats autoimmunity [8]
and inflammation in several experimental models [6,11,13],
the suppressive effect of apoptotic cell infusion on experimen-
tal arthritis is unknown.
Injection of Group A streptococcal cell wall (SCW) peptidog-
lycan–polysaccharide complexes induces an acute inflamma-
tion of the peripheral joints, followed by a chronic, erosive
arthritis in susceptible rats. This corresponds to an animal
model for rheumatoid arthritis (RA) [17,18]. The acute phase
is clinically evident within 24 hours after injection of SCW and
is characterized histologically by neutrophil infiltration into the
synovium. The chronic erosive arthritic stage, on the other
hand, is induced by T-cell-mediated and macrophage-medi-
ated immune responses, characterized by accumulation of
mononuclear cells with release of proinflammatory cytokines
and erosive destruction of subchondral and periarticular bone
and cartilage [18-20].
Systemic administrations of IL-4, TGFβ or an inhibitor of nitric
oxide have been shown to suppress pathogenesis of SCW
arthritis [19,20]. Macrophage depletion could also suppress
the chronic phase of the SCW-induced arthritis [21]. Oral
administration of SCW prior to systemic injection of SCW
substantially prevents the joint swelling and destruction typi-
cally observed during both acute and chronic phases of the
arthritis [18]. The effect of oral tolerance on SCW arthritis was
associated with an increase in circulating levels of TGFβ
accompanied by a decrease in inflammatory cytokines and
inhibition of the arthritic response [18]. Because macro-
phages have been identified as pathogenic in SCW-induced
RA and because TGFβ has a protective role on SCW-induced
RA, we proposed to test the efficiency of apoptotic cell infu-
sion to modulate the arthritic response.
Materials and methods
Animals, induction and monitoring of arthritis
Arthritis was induced in pathogen-free Lewis female rats
(Charles River Laboratories, Wilmington, MA, USA) by intra-
peritoneal injection of Group A SCW peptidoglycan–polysac-
charide complexes (30 μg rhamnose/g body mass; Lee
Laboratories, Grayson, GA, USA) [18]. Animals were housed
in a specific pathogen-free rodent facility at the National Insti-
tute of Dental and Craniofacial Research, National Institutes of
Health. All animal studies were performed according to
National Institutes of Health guidelines for use and care of live
animals and were approved by the Animal Care and Use Com-
mittee of National Institute of Dental and Craniofacial
Research.
Acute and chronic joint pathology was clinically monitored and
the articular index was determined, as previously described
[17,19]. Briefly, the degree of joint swelling was monitored
using a plethysmometer (UGO Basile, Varese, Italy). Radio-
graphs taken with direct exposure (1:1) on X-Omat TL Kodak
film using 60-kV, 345-mA, 60-s exposure by a Faxitron X-ray
machine (Faxitron X-ray Corporation, Buffalo Grove, IL, USA)
were evaluated for soft tissue swelling, joint space narrowing,
bone erosions and deformity. On days 25 and 26 after SCW
immunization, joints were harvested and fixed with neutral
10% formalin, extracted, embedded in paraffin and cut into 5
μm sections for H & E staining.
Preparation of apoptotic cells
Rat thymocytes were gamma-irradiated (1,500 rad) and cul-
tured in complete DMEM medium at 5% carbon dioxide and
37°C for 4 to 6 hours as previously described [22]. This cul-
ture allowed apoptotic changes to occur. Cells were 90 to
95% apoptotic as determined by Annexin-V staining and 7-
Aminoactinomycin D exclusion before washing with PBS and
intraperitoneal injection into the indicated rats at 2 × 108 cells
per animal at the same time as SCW (two different injections).
This corresponds to the early apoptotic state, as indicated by
7-Aminoactinomycin D exclusion. Cells were 70 to 80% apop-
totic 3 hours after irradiation and were 90 to 95% apoptotic 6
hours after apoptosis induction.
Flow cytometry
The spleens, inguinal and mesenteric lymph nodes were
removed aseptically and single-cell suspensions were pre-
pared. Peripheral T cells were also analyzed after retro-orbital
bleeding and red cell lysis with ACK lysing buffer (Biowhit-Available online http://arthritis-research.com/content/11/4/R104
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taker, Walkersville, MD, USA). One to 5 × 105 cells were
resuspended in PBS (Biowhittaker) containing 1% BSA
(Irvine, Santa Ana, CA, USA). For surface staining, cells were
incubated with FITC-conjugated anti-rat CD4 (Caltag, San
Francisco, CA, USA) and allophycoyanin-conjugated anti-
CD25 mAbs (BD Biosciences, San Jose, CA, USA) on ice for
30 minutes. After two washes with PBS-% BSA, cells were
prepared for intracellular phycoerythrin-labeled Foxp3 mAb
staining according to the manufacturer's recommendations
(eBiosciences, San Diego, CA, USA). Cells were then resus-
pended in 0.5 ml PBS-1% BSA for analysis by flow cytometry
(FACSCalibur®; BD Biosciences) using CellQuest Pro® soft-
ware (BD Biosciences).
Cell culture and cytokine assays
Peritoneal macrophages were obtained 4 days after disease
induction from peritoneum cavity exudates. Briefly, after four
washes with cold PBS of the peritoneum cavity of each rat,
enriched macrophage suspension was adjusted to 1 × 106
cell/ml and cultured with or without lipopolysaccharide (LPS)
stimulation (50 ng/ml) in complete DMEM medium containing
10% (vol/vol) heat-inactivated FBS, 2 mM glutamine, 15 mM
Hepes, 1% nonessential amino acids, 1 mM sodium pyruvate,
penicillin (100 μg/ml), streptomycin (50 μg/ml) and 50 μM 2-
mercaptoethanol (all from Biowhittaker). Supernatants were
then collected at 24 hours and tested for TNF by ELISA (Bio-
Legend, San Diego, CA, USA) following the manufacturer's
instructions. Rats were blood punctured in the retro-orbital
sinus at days 1, 4, 6 and 11 for total TGFβ quantification in the
plasma after a 1/20 dilution by ELISA (Promega, Madison, WI,
USA) following the manufacturer's instructions.
Statistical analysis
Group comparisons of parametric data were made by Stu-
dent's t test. We used the Mann-Whitney rank-sum test for
nonparametric data. We assessed score comparisons
between groups by one-way analysis of variance, and when
significant differences were found we used Dunn's method to
identify differences compared with the control group. We per-
formed statistical analyses with SigmaStat 3.11 software
(Systat Software, Richmond, CA, USA). We tested data for
normality and variance, and considered P < 0.05 significant.
Statistical analysis was assessed when the number of experi-
mented animals or conditions was sufficient.
Results
Injection of apoptotic cells prevents SCW-induced 
arthritis in susceptible rats
We first assessed the impact of apoptotic cell injection in a
model of inducible arthritis after injection of SCW peptidogly-
can–polysaccharide complexes in susceptible Lewis rats.
Injection of 3 to 4 mg SCW per rat induced a first acute phase
of arthritis for about 6 days after injection, followed by a reso-
lution phase and a chronic phase at around day 15 after immu-
nization (Figure 1a). Injection of apoptotic cells with SCW
significantly reduced the severity of the arthritis in both the
acute phase and the chronic phase as determined by an artic-
ular index (P < 0.001 SCW vs. SCW + apoptotic cells; Figure
1a and Table 1). Apoptotic cell injection alone (in the absence
of SCW) did not induce any sign of arthritis occurrence (Fig-
ure 1a).
The dramatic effect of apoptotic cell injection on the course of
SCW-induced arthritis development could also be observed
at the level of joint swelling and bone destruction assessed by
autoradiography (Figure 1b) or using a plethysmometer (Fig-
ure 1c) during the chronic phase of arthritis compare with
SCW injection alone. Consistent with the substantial amelio-
ration of the disease score, administration of apoptotic cells
also dramatically reduced the synovial inflammatory cell infiltra-
tion and bone destruction (Figure 1d).
At the time of arthritis induction by SCW injection, therefore,
administration of apoptotic cells significantly decreases the
course of arthritis occurrence and the severity of the disease,
demonstrating the immunomodulatory properties of apoptotic
cells.
Table 1
Apoptotic cell injection prevents rats from SCW-induced arthritis development
Acute phase (day 3) Remission phase (days 10 and 11) Chronic phase (days 24 to 30)
SCW + PBS SCW + Apo SCW + PBS SCW + Apo SCW + PBS SCW + Apo
AI scorea 4.2 ± 0.8 2.0 ± 0.6 1.7 ± 0.7 0.5 ± 0.7 4.9 ± 3.5 1.3 ± 1.4
n 12 13 5 6 5 6
P valueb 0.041 0.052 0.030
Incidencec 10/12 7/13 4/5 2/6 5/5 3/6
Pooled results from of three independent experiments. n, number of rats. aArticular index score presented as mean ± standard error of the mean. 
bCompared between streptococcal cell wall (SCW) and SCW + apoptotic cells (Apo); Mann-Whitney rank-sum test, one tail. cNumber of rats 
with disease among the rats of each group; the lower number of animals in the chronic phase is due to sacrifice of animals at the end of the acute 
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Figure 1
Apoptotic cell injection prevented streptococcal cell wall-induced arthritis Apoptotic cell injection prevented streptococcal cell wall-induced arthritis. (a) Rats were injected with streptococcal cell wall (SCW) in addition to 
apoptotic cells (Apo, 2 × 108 cells) or with Apo only and were followed for arthritis occurrence, scored using an articular index for each animal (mean 
± standard error of the mean (SEM); n = 3 or 4 rats for each group). P < 0.001, SCW vs. SCW + Apo. (b) Joint swelling and bone destruction were 
assessed by X-ray exposure in the different groups (representative animals from each group) as well as (c) the joint volume using a plethysmometer, 
both at day 21 post SCW injection (mean ± SEM; *P < 0.05 vs. PBS, Apo and SCW + Apo). (d) H & E analysis of the joints in rats with the indi-
cated treatments at days 25 and 26 post SCW injection. A representative rat from each group is shown (magnification 20×). Each group contained 
three to six rats. The experiment was repeated three times with similar results.Available online http://arthritis-research.com/content/11/4/R104
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Injection of apoptotic cells decreases the 
proinflammatory response of macrophages
Since apoptotic cells induced in situ have been demonstrated
to increase the level of circulating TGFβ [8] and because pre-
vious studies have indicated that the systemic levels, not the
local levels (that is, joints), of TGFβ were positively associated
with the amelioration of SCW arthritis [17], we measured cir-
culating TGFβ in the recipient rats at days 1, 4, 6 and 11 after
induction of arthritis in the different conditions. Although circu-
lating levels of total TGFβ between days 4 and 11 were not
significantly modified in the different conditions tested, an
increase of total TGFβ was observed in rats receiving apop-
totic cells alone on day 11 (data not shown). The levels of total
TGFβ, however, were significantly lower 1 day after injection
in the SCW-injected groups (SCW vs. PBS, P < 0.01; SCW
+ apoptotic cells vs. PBS, P < 0.05; Figure 2a). To better
appreciate the effects on TGFβ, the active form of circulating
TGFβ was then measured on days 4 and 11 after SCW injec-
tion. Although no statistical differences between the various
groups were observed (day 4, mean ± standard error of the
mean: PBS, 96.3 ± 9.4 pg/ml; apoptotic cells, 242.5 ± 96.2
pg/ml; SCW, 171.6 ± 103.5 pg/ml; apoptotic cells + SCW,
157.0 ± 30.7 pg/ml; two to six rats per group), an increase of
active TGFβ was seen at day 4 in rats receiving apoptotic cells
alone.
Since apoptotic cell injection reduced the severity of arthritis
induced by SCW immunization and macrophages involved in
apoptotic cell capture exhibited anti-inflammatory features
[23], we investigated ex vivo macrophage functional charac-
terization as assessed by the levels of the inflammatory
cytokine TNF. Macrophages from the peritoneum cavity of rats
receiving SCW alone, apoptotic cells alone or SCW plus
apoptotic cells were enriched at day 4 and cultured overnight.
TNF was tested in the culture supernatant. SCW immunization
induced a marked activation of peritoneal macrophages as
demonstrated by a strong spontaneous secretion of TNF com-
pared with rats receiving only PBS or apoptotic cells (Figure
2b, left panel). Injection of apoptotic cells with SCW
decreased spontaneous TNF release in the culture superna-
tants compared with SCW only (Figure 2b, left panel).
To confirm these data, we then challenged the enriched mac-
rophages from the indicated rats to determine their response
to LPS stimulation. As expected, macrophages from PBS-
treated rats produced TNF in response to LPS, slightly more
than those from rats injected with apoptotic cells alone 4 days
earlier (Figure 2b, right panel). Macrophages from SCW-
injected rats produced increased levels of TNF in response to
LPS. Injection of apoptotic cells with SCW prevented macro-
phage from LPS-induced TNF secretion (Figure 2b, right
panel).
Co-injection of apoptotic cells to SCW therefore reduced
SCW-induced macrophage activation in vivo. This reduction
of activation may be related to apoptotic cell uptake.
Apoptotic cell injection leads to increase in 
CD4+CD25+Foxp3+ regulatory T cells
Uptake of apoptotic bodies by macrophages has been shown
to induce Treg generation [8,13], so we investigated the role
of such a Treg population in the control of SCW-induced
arthritis by apoptotic cell injection. We assessed the Treg pop-
ulation based on their constitutive expression of the transcrip-
tional factor Foxp3 in the blood, spleen, mesenteric and
inguinal lymph nodes 4 and 26 days after arthritis induction.
Apoptotic cell injection by itself induced an increase of the
percentage of Tregs among the CD4+ T cells in all tested
organs (including the spleen and draining inguinal lymph
nodes) at day 4, and at day 26 in the spleen, mesenteric lymph
nodes and considerably in the blood (Figure 2d; apoptotic
cells vs. PBS or SCW, P < 0.01; apoptotic cells vs. SCW +
apoptotic cells, P < 0.05). This observation confirms previous
results obtained in mice [8,12,13,24]. Whereas injection of
SCW did not induce any increase in the Treg population in all
organs tested on any day – the percentage of Tregs in SCW-
treated rats was similar to the percentage of Tregs in PBS-
treated rats (Figure 2c, d) – injection of apoptotic cells with
SCW immunization induced a significant increase in Tregs at
day 4 in blood (P < 0.05 vs. SCW alone; Figure 2c, right
panel). The Treg increase after apoptotic cell injection in
SCW-treated rats was also observed in the draining inguinal
lymph nodes without reaching statistical significance (P = not
significant vs. SCW alone; Figure 2c, middle panel).
At day 26 in all of the organs tested – in particular, in the site
of immunization with SCW (that is, the mesenteric lymph
nodes) – apoptotic cell injection induced a marked increase of
Tregs compared with SCW alone (Figure 2d, middle panel).
Indeed, the Treg increase observed in the mesenteric lymph
nodes at day 26, and not in the draining inguinal lymph nodes
(data not shown), of rats injected with SCW plus apoptotic
cells was as high as that observed in rats receiving only apop-
totic cell injection. The prevention of and decrease in inflam-
mation, joint swelling and bone destruction due to apoptotic
cell injection is therefore associated with reduced TNF secre-
tion by macrophage and Treg increase, especially at the
inflammatory site.
Discussion
Apoptotic cell injection has been previously shown to induce
a transient immunosuppressive environment, sufficient in ani-
mal models to reduce inflammation [6,13] or to favor tolerance
toward allo-antigens [13,22] or self antigens [8]. RA is an
autoimmune disease characterized by a lack of apoptosis
leading to hyperplasia of the synovial lining. The macrophage
is one of the principal cell types that contribute to the patho-Arthritis Research & Therapy    Vol 11 No 4    Perruche et al.
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Figure 2
Apoptotic-cell injection prevents streptococcal cell wall-induced arthritis by macrophageactivation prevention and regulatory T cells increase Apoptotic-cell injection prevents streptococcal cell wall-induced arthritis by macrophageactivation prevention and regulatory T cells increase. (a) 
Rats from the different groups were punctured into the retro-orbital sinus at day 1 to quantify circulating total transforming growth factor beta (TGFβ) 
by ELISA in the serum (mean ± standard error of the mean (SEM); n = 3 rats per group, excepted PBS n = 2). Apo, apoptotic cells; SCW, strepto-
coccal cell wall. Δ>P < 0.01 and *P < 0.05 compared with PBS-injected rats. (b) Macrophages issued from rats of the different groups were har-
vested from the peritoneum cavity 4 days after injection. TNF (mean ± SEM of the duplicate measurements) was tested by ELISA in the supernatant 
of the cultured macrophages (1 × 106 cell per condition) from rats from each group (n = 3 to 4 rats) untreated (left panel) or after lipopolysaccharide 
(LPS) (50 ng/ml) overnight stimulation (right panel). Experiment repeated twice with similar results. (c) At day 4 and (d) at day 26 after SCW immu-
nization, rats were sacrificed and the blood, spleen, inguinal lymph nodes (DLN) and mesenteric lymph nodes (MLN) were collected to analyze 
Foxp3+ regulatory T cells by flow cytometry. Results expressed as mean ± SEM; three animals/group; *P < 0.05. (c) Results for MLN and spleen 
expressed as mean ± SEM of the duplicate experiments, corresponding to two or three rats pooled together and repeated twice, not allowing statis-
tical analysis. *P < 0.05 compared with PBS-treated or SCW-treated rats (four to six individual animals). (d) Experiment was repeated twice with 
similar results.Available online http://arthritis-research.com/content/11/4/R104
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genesis of RA, since macrophage depletion suppresses the
chronic phase of SCW-induced arthritis [21]. This is why we
decided to infuse apoptotic cells in a RA model: providing
apoptotic cells to macrophages may change their proinflam-
matory behavior. In the present article, we showed that apop-
totic cell injection prevents macrophages from SCW-induced
TNF secretion. In addition, apoptotic cell infusion leads to an
increased of Tregs in the draining lymph nodes. This was asso-
ciated with a decrease in the symptoms and the severity of
SCW-induced arthritis.
Both acute and chronic joint inflammations were significantly
inhibited by apoptotic cell injection – including reduction of
swelling and decreased tissue and bone destruction. The syn-
ovial inflammatory cell infiltration and TNF production were
also markedly suppressed. Our data indicate that delivery of
apoptotic cells in vivo even in the periphery may initiate anti-
inflammatory mechanisms to antagonize the joint inflammatory
response. Macrophages exposed by apoptotic cells seemed
to be less efficient to induce and sustain SCW inflammation.
Indeed, apoptotic cell injection acts in two different ways. First,
apoptotic cells together with phagocytes that digest apoptotic
cells in a very efficient manner induce an anti-inflammatory
microenvironment. This first sequential event directly targets
the acute phase induced by the SCW complexes and may pre-
vent effector T-cell activation and migration to inflammatory
sites such as joints and bones. The apoptotic cell injection-
induced TGFβ increase also correlates with the Treg increase.
Then, after the uptake of apoptotic cells, professional phago-
cytes such as macrophages become more resistant to inflam-
matory signals [23,25] and cytokines, as we observed here
with the decrease of TNF secretion after LPS stimulation. This
second sequential event targets phagocytes and may prevent
occurrence of the chronic phase. This is in line with the work
of Richards and colleagues showing that macrophage deple-
tion alters the chronic phase of SCW-induced RA [21].
Macrophages, after the uptake of apoptotic cells, may then
release TGFβ- which we detected in the periphery very early
after apoptotic cell infusion – and may contribute to the resist-
ance of macrophages to LPS stimulation, as previously
described [23]. The reduction of circulating TGFβ in SCW-
induced inflammation at day 1 and the slight increase in circu-
lating active TGFβ at day 4 in apoptotic cell-treated animals at
the time of articular index reduction also suggests a critical
role for endogenous TGFβ in the control of inflammation. The
Treg increase observed at day 4 in the inguinal draining lymph
nodes of animals receiving apoptotic cells plus SCW also
supports this point. The increase of TGFβ we observed in the
circulation after apoptotic cell injection alone is in line with
another experimental model, where apoptotic cells were
induced in vivo and led to a TGFβ increase for 4 days with a
peak at 24 hours after apoptotic cell induction [8]. As previ-
ously shown in tolerance induction by oral administration of
SCW peptide [18], TGFβ is mainly responsible for the preven-
tion of the disease; apoptotic cell administration may induce a
similar effect.
In addition to macrophages, immature dendritic cells may also
uptake apoptotic cells and then may produce less IL-1β, IL-6
and TNF in response to LPS stimulation [4] – all of these proin-
flammatory cytokines were found at elevated levels in RA
patients or in collagen-induced arthritis mice. The effects may
be ascribed at least in part to the TGFβ production by imma-
ture dendritic cells upon digestion of apoptotic cells [26].
Moreover, IL-1β has been demonstrated as an important medi-
ator of SCW-induced arthritis by promoting Th17 differentia-
tion [27]. One may speculate that apoptotic cell infusion by
downregulating IL-1β production in responses to inflammatory
signals [4] controls Th17 response and subsequent arthritis
development.
The second effect mediated by apoptotic cell injection may
implicate the release of TGFβ, as described previously
[3,13,23]. The elevated concentration of TGFβ permits the
Treg increase, preventing activation of specific T cells respon-
sible for the chronic phase of arthritis. The fact that the Treg
increase was observed in our model only in the lymph nodes
draining SCW-induced pathology further supported this idea.
In line with this notion, it has been shown that adoptive transfer
of CD25+ Tregs effectively decreases collagen-induced arthri-
tis [28]. Because Th17 cells has been suggested to be
involved in the induction of arthritis in an experimental model of
spontaneous arthritis [29,30], apoptotic cell injection may also
increase T-cell polarization to Tregs instead of Th17 differenti-
ation by increasing the TGFβ levels.
Conclusions
In the present article we have shown that apoptotic cell injec-
tion can significantly decrease the occurrence and the severity
of SCW-induced RA. Apoptotic cell injection offers a tool to
control and prevent macrophage-induced SCW inflammation.
Apoptotic cell prevention of SCW-induced RA seems to be
achieved sequentially: first after uptake of apoptotic cells by
phagocytes, in particular macrophages that decrease their
response to LPS; and then through a Treg increase in lym-
phoid organs, in particular in the draining lymph nodes, thus
preventing and controlling SCW inflammation. These findings
may provide insight into understanding the pathogenesis of
chronic inflammation and autoimmune disease, and may also
offer clues to manipulate Tregs and macrophages by apop-
totic cell injection. The data are in line with our previous work
suggesting the potential of apoptotic cells to treat ongoing
autoimmune disease such as experimental autoimmune
encephalomyelitis.
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